STARDUST is an open-label, two-arm randomized controlled trial, aimed at evaluating the
effects of liraglutide on peripheral perfusion, as compared with the aggressive treatment of
cardio-metabolic risk factors, in people with type 2 diabetes and peripheral artery disease.
The potential benefits for participants in the study include the possibility of improving
peripheral perfusion with drugs that have been evaluated as effective in controlling diabetes
and safe and protective for cardiovascular health.
The primary outcome of the study is the change of peripheral transcutaneous oxygen tension
between groups at three and six months. Participants in the study will be followed for 6
months in order to evaluate the effects of liraglutide and the change of other secondary
outcomes.